BioSpace News Archive

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced a poster presentation at the American Association for Cancer Research Annual Meeting 2021, being held virtually from April 10-15.

Freenome demonstrates potential for patient stratification and monitoring using its multiomics platform at the American Association for Cancer Research (AACR) Annual Meeting

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, presented a data update on the safety and tolerability of twice daily administered poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations.

Phase 2 trial of Amgen’s investigational KRASG12C inhibitor, sotorasib, demonstrated comparable efficacy between patients identified as KRASG12C positive using Guardant360 CDx liquid biopsy or tissue biopsy

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, presented preclinical data on the company’s novel protein secretion program during two poster sessions at the American Association for Cancer Research 2021 Virtual Annual Meeting.

Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the presentation of four posters highlighting research across its immuno-oncology programs at the American Association for Cancer Research virtual Annual Meeting.

Mersana Therapeutics, Inc. presented preclinical data from XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate, and XMT-2056, an Immunosynthen-based STING-agonist ADC at the Virtual 2021 American Association for Cancer Research Annual Meeting being held from April 10-15th.

Study demonstrates GMI-1757’s impact on immune cell infiltration and improvement of anti-PD-L1 therapeutic activity

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that new in vivo preclinical data were presented at the 2021 Annual Meeting of the American Association for Cancer Research.

PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, presented preclinical data on PC14586, the Company’s first-in-class, tumor-agnostic, small molecule p53 reactivator at the American Association for Cancer Research Annual Meeting 2021.